Eli Lilly and Company's acquisition of Kelonia Therapeutics marks a significant step forward in the development of in vivo CAR-T cell therapies. This deal, which is expected to close in the second half of 2026, will see Lilly acquire Kelonia for up to $7.00 billion in cash, inclusive of an upfront payment of $3.25 billion and subsequent payments upon achievement of certain clinical, regulatory, and commercial milestones. The acquisition is a strategic move for Lilly, as it expands their genetic medicine capabilities with Kelonia's novel in vivo gene delivery and integration technology, which has the potential for broad applicability. This technology, known as the in vivo gene placement system (iGPS®), uses specially engineered lentiviral-based particles to efficiently and selectively enter T-cells inside the body, allowing the patient's own body to generate chimeric antigen receptor T-cell (CAR-T) therapies that can treat underlying disease.
The acquisition is particularly exciting because it addresses significant barriers in the current CAR-T therapy landscape. Autologous CAR-T therapies have shown promise in treating various cancers, but their manufacturing, safety, and access issues limit their availability to only a fraction of eligible patients. Kelonia's in vivo platform has the potential to overcome these barriers by delivering rapid, durable responses in a simpler, off-the-shelf format. This could mean that more patients with relapsed or refractory multiple myeloma, a disease targeted by Kelonia's lead program, KLN-1010, will have access to effective treatment.
KLN-1010 is an investigational, one-time intravenous gene therapy that generates anti-B-cell maturation antigen (BCMA) CAR-T cells, targeting the BCMA protein expressed on the surface of multiple myeloma cells. Early clinical results presented at the 2025 American Society of Hematology Annual Meeting were highly encouraging, demonstrating promising tolerability and initial clinical validation. By eliminating the complexities of ex vivo patient-specific cell therapy manufacturing and pre-administration chemotherapy, KLN-1010 could represent a transformative advance in the treatment of multiple myeloma.
The acquisition of Kelonia by Lilly is a strategic move that leverages Kelonia's innovative technology and clinical progress. This partnership has the potential to accelerate the development and commercialization of KLN-1010, bringing a much-needed treatment option to patients with relapsed or refractory multiple myeloma. Additionally, the iGPS platform has the potential to broaden the reach of cell therapy beyond hematologic malignancies and transform treatment across a wide range of cancers and other serious diseases. This acquisition highlights Lilly's commitment to advancing genetic medicine and its potential to revolutionize the treatment of various diseases.
In my opinion, this acquisition is a significant milestone in the field of genetic medicine and CAR-T cell therapies. It showcases the power of collaboration between pharmaceutical giants and innovative biotech companies. By combining Lilly's resources and expertise with Kelonia's cutting-edge technology, this partnership has the potential to accelerate the development of life-changing treatments for patients with a wide range of diseases. The future of medicine is undoubtedly moving towards more personalized and effective therapies, and this acquisition is a testament to that progress.
